The appointment of Stu Dorman as Chief Commercial Officer is likely to positively impact IDEAYA Biosciences' stock in the short term. His extensive experience in oncology commercialization, including successful product launches at Gilead Sciences and Bristol Myers Squibb, suggests he will effectively lead IDEAYA's commercial strategies. This strategic hire indicates a strong focus on enhancing the company's market presence and product commercialization, which is crucial for a precision medicine oncology company.